CN107405335A - 治疗肌萎缩侧索硬化和神经病的方法 - Google Patents

治疗肌萎缩侧索硬化和神经病的方法 Download PDF

Info

Publication number
CN107405335A
CN107405335A CN201680018463.8A CN201680018463A CN107405335A CN 107405335 A CN107405335 A CN 107405335A CN 201680018463 A CN201680018463 A CN 201680018463A CN 107405335 A CN107405335 A CN 107405335A
Authority
CN
China
Prior art keywords
biotin
treatment
patient
purposes according
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680018463.8A
Other languages
English (en)
Chinese (zh)
Inventor
F.赛德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medday Pharmaceuticals
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107405335(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Priority to CN202010704334.2A priority Critical patent/CN111973592A/zh
Publication of CN107405335A publication Critical patent/CN107405335A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
CN201680018463.8A 2015-03-26 2016-03-25 治疗肌萎缩侧索硬化和神经病的方法 Pending CN107405335A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010704334.2A CN111973592A (zh) 2015-03-26 2016-03-25 治疗肌萎缩侧索硬化和神经病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
EP15305437.4 2015-03-26
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010704334.2A Division CN111973592A (zh) 2015-03-26 2016-03-25 治疗肌萎缩侧索硬化和神经病的方法

Publications (1)

Publication Number Publication Date
CN107405335A true CN107405335A (zh) 2017-11-28

Family

ID=52779582

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680018463.8A Pending CN107405335A (zh) 2015-03-26 2016-03-25 治疗肌萎缩侧索硬化和神经病的方法
CN202010704334.2A Pending CN111973592A (zh) 2015-03-26 2016-03-25 治疗肌萎缩侧索硬化和神经病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010704334.2A Pending CN111973592A (zh) 2015-03-26 2016-03-25 治疗肌萎缩侧索硬化和神经病的方法

Country Status (24)

Country Link
US (2) US10357480B2 (https=)
EP (2) EP3072513A1 (https=)
JP (1) JP6752874B2 (https=)
KR (1) KR20170131543A (https=)
CN (2) CN107405335A (https=)
AU (1) AU2016238759B2 (https=)
BR (1) BR112017020408A2 (https=)
CA (1) CA2980660A1 (https=)
CY (1) CY1122374T1 (https=)
DK (1) DK3273957T3 (https=)
EA (1) EA034394B1 (https=)
ES (1) ES2748354T3 (https=)
HR (1) HRP20191491T1 (https=)
HU (1) HUE046116T2 (https=)
IL (1) IL254619B (https=)
LT (1) LT3273957T (https=)
MA (1) MA41809B1 (https=)
ME (1) ME03567B (https=)
PL (1) PL3273957T3 (https=)
PT (1) PT3273957T (https=)
RS (1) RS59149B1 (https=)
SI (1) SI3273957T1 (https=)
SM (1) SMT201900548T1 (https=)
WO (1) WO2016151132A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
CN113164278A (zh) * 2018-12-11 2021-07-23 马优斯珀茨澳大利亚私人有限公司 粘合垫
CN116322709A (zh) * 2020-10-09 2023-06-23 Tx医生公司 使用硫酸葡聚糖的肌肉萎缩的治疗

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
FR2905868A1 (fr) * 2006-09-18 2008-03-21 Gemac Sa Composition destinee au traitement de la sclerose laterale amyotrophique
CN104602689A (zh) * 2012-07-26 2015-05-06 公共救济事业局-巴黎医院 生物素治疗多发性硬化的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86749C2 (en) 2002-09-27 2009-05-25 Байоджен Айдек Ма Инк. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
WO2012145746A1 (en) * 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
KR101951220B1 (ko) * 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
FR2905868A1 (fr) * 2006-09-18 2008-03-21 Gemac Sa Composition destinee au traitement de la sclerose laterale amyotrophique
CN104602689A (zh) * 2012-07-26 2015-05-06 公共救济事业局-巴黎医院 生物素治疗多发性硬化的用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164278A (zh) * 2018-12-11 2021-07-23 马优斯珀茨澳大利亚私人有限公司 粘合垫
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
CN116322709A (zh) * 2020-10-09 2023-06-23 Tx医生公司 使用硫酸葡聚糖的肌肉萎缩的治疗

Also Published As

Publication number Publication date
NZ735528A (en) 2021-09-24
AU2016238759A1 (en) 2017-10-05
JP6752874B2 (ja) 2020-09-09
US20190314342A1 (en) 2019-10-17
EP3072513A1 (en) 2016-09-28
CA2980660A1 (en) 2016-09-29
LT3273957T (lt) 2019-11-11
SMT201900548T1 (it) 2019-11-13
EP3273957A1 (en) 2018-01-31
EP3273957B1 (en) 2019-08-14
DK3273957T3 (da) 2019-11-11
US10357480B2 (en) 2019-07-23
IL254619B (en) 2020-03-31
WO2016151132A1 (en) 2016-09-29
SI3273957T1 (sl) 2019-11-29
PL3273957T3 (pl) 2020-01-31
EA034394B1 (ru) 2020-02-04
CY1122374T1 (el) 2021-01-27
ES2748354T3 (es) 2020-03-16
CN111973592A (zh) 2020-11-24
HRP20191491T1 (hr) 2019-11-15
IL254619A0 (en) 2017-11-30
KR20170131543A (ko) 2017-11-29
HUE046116T2 (hu) 2020-02-28
JP2018512451A (ja) 2018-05-17
US20180125825A1 (en) 2018-05-10
BR112017020408A2 (pt) 2018-06-05
MA41809A (fr) 2018-01-30
EA201792124A1 (ru) 2018-04-30
RS59149B1 (sr) 2019-09-30
MA41809B1 (fr) 2019-12-31
AU2016238759B2 (en) 2020-08-06
PT3273957T (pt) 2019-09-18
ME03567B (me) 2020-07-20

Similar Documents

Publication Publication Date Title
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
US20190314342A1 (en) Method for treating demyelinating neuropathy with biotin
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
HK1243938A1 (en) Biotin for treating demyelinating neuropathies
HK1243938B (en) Biotin for treating demyelinating neuropathies
NZ735528B2 (en) Biotin for treating demyelinating neuropathies
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
US8664209B2 (en) Daptomycin for multiple sclerosis
HK40008598A (en) Use of biotin for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171128

WD01 Invention patent application deemed withdrawn after publication